Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
PCRX 11.12.2024
About Gravity Analytica
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) --Pacira BioSciences, Inc.(NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
- Jefferies London Healthcare Conference on Tuesday, November 19that 3:00PM GMT (10:00AM ET).
- 36thAnnual Piper Sandler Healthcare Conference on Tuesday, December 3rdat 1:00PM ET.
Live audio of the events can be accessed by visiting the “Events” page of the company’s website atinvestor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.
About PaciraPacira BioSciences delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL®(bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, interscalene brachial plexus nerve block in adults, sciatic nerve block in the popliteal fossa in adults, and adductor canal block in adults for postsurgical pain management; ZILRETTA®(triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioverao®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visitwww.pacira.com.
Company Contact:Pacira BioSciences, Inc.Christian Pedetti(973) 254-4387Christian.pedetti@pacira.com